Technology
Health
Biotechnology

Heat Biologics

$0.575
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.028 (-4.64%) As of 12:11 PM EDT today
-$0.028 (-4.64%) Today

Why Robinhood?

You can buy or sell Heat Biologics and other stocks, options, ETFs, and crypto commission-free!

About HTBX

Heat Biologics, Inc. Common Stock, also called Heat Biologics, is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. Read More The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Durham, NC.

Employees
30
Headquarters
Durham, North Carolina
Founded
2008
Market Cap
20.69M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
160.92K
High Today
$0.623
Low Today
$0.55
Open Price
$0.623
Volume
110.39K
52 Week High
$2.24
52 Week Low
$0.55

Collections

Technology
Health
Biotechnology
Medical
Cancer Prevention
2013 IPO
US
North America

HTBX Earnings

-$2.81
-$1.92
-$1.04
-$0.15
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 14, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.